1. Detecting Resistance to Therapeutic ALK Inhibitors in Tumor Tissue and Liquid Biopsy Markers: An Update to a Clinical Routine Practice
   Paul Hofman, 2021, Cells CrossRef
2. Immunotherapy and Vaccination in Surgically Resectable Non-Small Cell Lung Cancer (NSCLC)
   Li-Chung Chiu et al, 2021, Vaccines CrossRef
3. Safety of Surgery after Neoadjuvant Targeted Therapies in Non-Small Cell Lung Cancer: A Narrative Review
   Tomasz Marjanski et al, 2021, IJMS CrossRef
4. Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitor-Associated Cardiotoxicity: A Recent Five-Year Pharmacovigilance Study
   Yihan Liu et al, 2022, Front. Pharmacol. CrossRef
5. Targeting Wnt/Beta-Catenin Signaling in HPV-Positive Head and Neck Squamous Cell Carcinoma
   Faris F. Brkic et al, 2022, Pharmaceuticals CrossRef
6. Pulmonary toxicity in driver gene positive non-small cell lung cancer therapy
   Yi-Pu Zhao et al, 2022, Current Medical Research and Opinion CrossRef
7. Anaplastic lymphoma kinase tyrosine kinase inhibitors associated gastrointestinal obstruction, perforation, and ulceration: an analysis of the FDA adverse event reporting system database (FAERS)
   Jing Huang et al, 2022, Int J Clin Pharm CrossRef
8. Real-World Treatment and Outcomes of ALK-Positive Metastatic Non–Small Cell Lung Cancer in a Southeast Asian Country
   Mau Ern Poh et al, 2023, CMAR CrossRef
9. Cardiac arrhythmias associated with anaplastic lymphoma kinase (ALK) inhibitors: an analysis of the FDA Adverse Event Reporting System (FAERS)
   Feifei Wang et al, 2023, Expert Opinion on Drug Safety CrossRef
10. Interstitial lung disease risk of anaplastic lymphoma kinase tyrosine kinase inhibitor treatment of non-small cell lung cancer: a real-world pharmacovigilance study
    Min Zhao et al, 2023, Expert Opinion on Drug Safety CrossRef
11. In vitro investigation of the binding characteristics of dacomitinib to human α 1-acid glycoprotein: Multispectral and computational modeling
    Zhe-Ying Hu et al, 2024, Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy CrossRef
12. Active and machine learning-enhanced discovery of new FGFR3 inhibitor, Rhapontin, through virtual screening of receptor structures and anti-cancer activity assessment
    Qingxin Zeng et al, 2024, Front. Mol. Biosci. CrossRef
13. Progression patterns, resistant mechanisms and subsequent therapy for ALK-positive NSCLC in the era of second-generation ALK-TKIs
    Lige Wu et al, 2024, J Transl Med CrossRef
14. SARCOID-LIKE REACTION RELATED TO ALK-ROS INHIBITORS IN LUNG CANCER PATIENTS.
    Clara Morin et al, 2024, Respiratory Medicine and Research CrossRef
15. Locally advanced/metastatic non-small-cell lung cancer in Lebanon: focus on ALK tyrosine kinase inhibitors
    Arafat Tfayli et al, 2024, Future Oncology CrossRef